Therapeutic Asset Ratings
414 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Amb-05X
Colorectal Cancer
M.D. Anderson Cancer Center
P2
CC
(46)
Ametumumab
Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
P2
CC
(46)
Amt-676
Colorectal Cancer
Multitude Therapeutics Inc.
P2
CC
(46)
Artesunate
Colorectal Cancer
Metanoic Health Ltd.
P2
CC
(46)
aur109
Colorectal Cancer
Aurigene Discovery Technologies Limited
P2
CC
(46)
Bemalenograstim Alfa
Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
CC
(46)
bi 907828
Colorectal Cancer
Institut Bergonié
P2
CC
(46)
cc-5013
Colorectal Cancer
Sun Yat-sen University
P2
CC
(46)
Ciprofloxacin
Colorectal Cancer
Virginia Commonwealth University
P2
CC
(46)
dsp107
Colorectal Cancer
Kahr Bio Australia Pty Ltd
P2
CC
(46)
Eliglustat
Colorectal Cancer
Chinese PLA General Hospital
P2
CC
(46)
eo2040
Colorectal Cancer
Enterome
P2
CC
(46)
Fianlimab
Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
CC
(46)
Fulzerasib
Colorectal Cancer
Zhejiang University
P2
CC
(46)
Futibatinib
Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
P2
CC
(46)
ibi363
Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
P2
CC
(46)
IBUPROFEN
Colorectal Cancer
Cairo University
P2
CC
(46)
IMMUNOGLOBULIN G1, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4) (HUMAN-MUS MUSCULUS MONOCLONAL M3 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL M3 .KAPPA.-CHAIN, DIMER
Colorectal Cancer
Merck Sharp & Dohme LLC
P2
CC
(46)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P2
CC
(46)
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
Colorectal Cancer
M.D. Anderson Cancer Center
P2
CC
(46)
Imu-201 (Pd1-Vaxx)
Colorectal Cancer
University of Southampton
P2
CC
(46)
Leronlimab
Colorectal Cancer
CytoDyn, Inc.
P2
CC
(46)
LOBAPLATIN
Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P2
CC
(46)
Losartan
Colorectal Cancer
Ain Shams University
P2
CC
(46)
Mirabegron
Colorectal Cancer
Zhejiang Provincial People's Hospital
P2
CC
(46)
Showing 126 to 150 of 414 assets
Previous
Page 6 of 17
Next
